褪黑素能否改善初次全髋关节置换术后的睡眠?一项随机双盲安慰剂对照试验
该随机双盲安慰剂对照试验纳入139例完成方案的初次择期全髋关节置换术患者,术后每晚服用5 mg褪黑素或安慰剂共14天。褪黑素组术后第14天患者报告结局测量信息系统睡眠障碍评分显著低于安慰剂组,但两组Epworth嗜睡评分无显著差异;褪黑素可能增加术后第1至3天睡眠时长,但获益在术后第3天后可能减弱。
要点
- 褪黑素组与安慰剂组术后Epworth嗜睡评分无显著差异(6.0±4.0 vs 6.8±4.5,P=0.35)。
- 褪黑素组术后第14天患者报告结局测量信息系统睡眠障碍评分显著低于安慰剂组(52.5±9.3 vs 56.3±9.2,P=0.040)。
- 褪黑素可能促进术后第1至3天睡眠时长,但潜在获益在术后第3天后可能减弱。
核心结论
- 褪黑素可能不能改善全髋关节置换术后整体睡眠质量(以Epworth嗜睡评分衡量)。
- 褪黑素可能促进术后第1至3天睡眠时长,但潜在获益在术后第3天后可能减弱。
- 褪黑素安全,可考虑用于出现早期术后睡眠障碍的全髋关节置换术患者。
研究设计与样本
- 前瞻性随机双盲安慰剂对照试验,纳入2021年7月至2024年3月期间接受初次择期全髋关节置换术的患者。
- 患者随机接受每晚5 mg褪黑素或安慰剂共14天,完成研究方案者共139例,其中安慰剂组64例、褪黑素组75例。
主要发现
- 两组术后Epworth嗜睡评分相当(褪黑素组6.0±4.0 vs 安慰剂组6.8±4.5,P=0.35)。
- 褪黑素组术后第2天睡眠时长显著多于安慰剂组(6.5±1.7 vs 5.7±2.4,P=0.017)。
- 术后第1至3天平均睡眠时长褪黑素组为6.1±1.6、安慰剂组为5.7±2.0(P=0.14),未达统计学显著。
- 术后第2天夜间觉醒次数褪黑素组为2.7±1.5、安慰剂组为3.1±2.0(P=0.28),未达统计学显著。
- 术后患者报告结局测量信息系统睡眠障碍评分褪黑素组显著低于安慰剂组(52.5±9.3 vs 56.3±9.2,P=0.040)。
关键数值与推荐
- 褪黑素用法为术后每晚5 mg,共14天。
- 睡眠障碍采用患者报告结局测量信息系统睡眠障碍表在术前和术后第14天评估。
- 睡眠质量采用Epworth嗜睡评分评估。
临床怎么用
- 作者认为褪黑素安全,可考虑用于出现早期术后睡眠障碍的全髋关节置换术患者。
- 作者指出针对术后睡眠障碍的标准化推荐尚未建立。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sleep impairment following total hip arthroplasty (THA) is common and may decrease patient satisfaction and early recovery. Standardized postoperative recommendations for sleep disturbance (SD) have not been established. We aimed to assess whether melatonin use improves sleep quality and quantity in the acute period following THA. METHODS: Patients undergoing primary, elective THA between July 2021 and March 2024 were prospectively enrolled and randomized to receive either 5 mg of melatonin or a placebo nightly for 14 days postoperatively. Participants recorded nightly pain scores on the visual analog scale, the number of hours slept, and the number of nighttime awakenings in a sleep diary. SD was assessed preoperatively and on postoperative day (POD) 14 using the patient-reported outcome measurement information system SD form. Epworth Sleepiness Scores (ESS) were collected to assess sleep quality. Of the 139 patients who completed the study protocol, there were 64 patients in the placebo group and 75 patients in the melatonin group. RESULTS: Both groups demonstrated comparable postoperative ESS (melatonin: 6.0 ± 4.0; placebo: 6.8 ± 4.5, P = 0.35). Melatonin patients experienced significantly more hours slept on POD two (6.5 ± 1.7; 5.7 ± 2.4, P = 0.017) and averaged over POD one to three (6.1 ± 1.6; 5.7 ± 2.0, P = 0.14), although this was not statistically significant. Fewer nighttime awakenings in the melatonin group were observed on POD 2 (2.7 ± 1.5; 3.1 ± 2.0, P = 0.28), although this was not statistically significant. The melatonin group demonstrated significantly lower postoperative patient-reported outcome measurement information system SD scores (52.5 ± 9.3; 56.3 ± 9.2, P = 0.040). CONCLUSIONS: Melatonin may not improve overall postoperative sleep quality following THA as measured by the ESS. Melatonin may promote sleep duration in the POD one to three period, although potential benefits wane after POD three. Melatonin is safe and can be considered for THA patients experiencing early postoperative SD. LEVEL OF EVIDENCE: I.
引用
- Haider MA, Lawrence KW, Christensen T, et al. Does Melatonin Improve Sleep Following Primary Total Hip Arthroplasty? A Randomized, Double-Blind, Placebo-Controlled Trial. J Arthroplasty. 2025. PMID: 40383169. doi:10.1016/j.arth.2025.05.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。